Long-term Effect of Lanthanum Carbonate on Bone

Completed

Conditions studied: Hyperphosphatemia

In brief

Patients enrolled in a previous study (SPD405-309), who were exposed to lanthanum carbonate (Fosrenol), were eligible to continue on any prescribed treatment for hyperphosphatemia, including lanthanum carbonate (Fosrenol), for an additional 5 years. Patients were being observed for any bone adverse events or other serious adverse events, as well as the collection of mortality data.

Key facts

Study ID
NCT00557323
Run by
Shire
People needed
34
Starts
2007-03-15
Expected to finish
2010-08-31
Last updated by the study team
2021-07-13

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.